Amino acid supplement

Glycine

Glycine is a non-essential amino acid; the app lists a half-life of about 4 hours, and 3 g before bedtime is the dose in the small sleep trials.1,2

Strong evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Glycine after one dose: 50% at ~4 h, 25% at 8 h, 12.5% at 12 h.

Drawn from the half-life in the app's model, ~4 h. The model's figures

Glycine is a non-essential amino acid, and mammals can produce sufficient amounts of it via de novo synthesis.1 Bannai and colleagues, Frontiers in Neurology, 2012, give approximately 45 g as the amount of endogenous glycine synthesised in humans, with no time period stated, and 3 to 5 g as the amount ingested from the daily diet.1 Lizzo and colleagues, Frontiers in Aging, 2022, give a different split: about 3 g a day from a regular Western diet and an estimated 1.5 to 3 g a day from endogenous synthesis.3 The app files glycine as a supplement (amino acid) taken by mouth, with a typical dose of 3 to 5 g/day. The app grades the evidence for glycine as strong. Soh and colleagues, GeroScience, 2024, included 47 articles describing 50 studies in a systematic review of glycine in adults, and note that the longer-term studies of sleep in healthy people had small samples and a high risk of bias.2 The app's notes also describe glycine as a glutathione precursor and a component of the GlyNAC stack, which Kumar and colleagues define as a "combination of glycine and N-acetylcysteine [NAC]".4

Bannai and colleagues write that glycine acts as an inhibitory neurotransmitter via glycine receptors in the peripheral and central nervous system.1 They add that it also acts as an excitatory co-agonist at the N-methyl-d-aspartate subtype of glutamate receptors (NMDARs).1 The app's notes say glycine lowers core body temperature via vasodilation and deepens slow-wave sleep. The primary reports reviewed here describe the temperature and vasodilation mechanism in rats, and Soh and colleagues' discussion states that, in healthy populations, oral glycine before bedtime improves sleep by promoting hypothermia and vasodilation, citing earlier work.2

Kawai and colleagues, Neuropsychopharmacology, 2015, studied rats and reported that "oral administration of glycine-induced non-rapid eye movement (REM) sleep and shortened NREM sleep latency with a simultaneous decrease in core temperature".5 In the same rat work, oral and intracerebroventricular glycine raised cutaneous blood flow in a dose-dependent manner, and ablating the suprachiasmatic nucleus (SCN) "completely abolished the sleep-promoting and hypothermic effects of glycine".5 The authors conclude that "exogenous glycine promotes sleep via peripheral vasodilatation through the activation of NMDA receptors in the SCN shell", a conclusion drawn in rats.5 A review by Bannai and Kawai, Journal of Pharmacological Sciences, 2012, reports that oral glycine in rats raised plasma and cerebrospinal fluid glycine and lowered core body temperature, and proposes that the temperature decline might underlie glycine's effect on sleep.6 In the rat experiment inside the Bannai 2012 paper (2 g/kg glycine by gavage), plasma melatonin was not significantly different between glycine and vehicle.1 Glycine is also one of the amino acids glutathione is built from: Lizzo and colleagues write that glutathione "is produced from the amino acids cysteine, glycine, and glutamate".3 Kumar and colleagues write that "GSH synthesis requires both glycine and cysteine, and both are provided by GlyNAC".4

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~4 h
Bioavailability
99%
Typical dose
3–5 g/day
Route
Oral
Time to peak
~1 h

The second column of the table holds the app's own figures, shown beside what the sources report.

Table 3.1Half-life and pharmacokinetics4 rows
ParameterApp's figureReported in the sources
Half-life~4 hNo half-life figure for oral glycine in people was identified in the PubMed records returned by searches on glycine pharmacokinetics, or in the trial texts reviewed here.
Bioavailability99%No absolute bioavailability figure was identified; Lizzo and colleagues, after a GlyNAC dose, write that "glycine and NAC are readily absorbed after oral intake within 1 h at all three active doses".3
Time to peak~1 hLizzo and colleagues cite a published tmax of approximately 75 min for glycine in the blood plasma of healthy volunteers, and took their samples 60 min after the dose.3
Duration of effect~6 hNo duration figure for glycine in people was identified in the sources reviewed.

Gannon and colleagues, American Journal of Clinical Nutrition, 2002, tested nine healthy subjects over a 2-hour period after ingestion of 1 mmol glycine/kg lean body mass and report that plasma glycine and glucagon concentrations "were elevated after the ingestion of glycine".7 In the GlyNAC dosing trial, Lizzo and colleagues report a "dose-dependent increase of circulating levels of glycine in blood plasma measured at 60 min after dose intake at all three doses".3

4

Human studies

Table 4.1Human studies5 rows
Study and yearDesignPeopleDose and lengthMain result
Bannai and colleagues, Frontiers in Neurology 20121Randomized single-blinded crossover trial; supported in part by the PROBRAIN programme, first author at Ajinomoto Co., Inc.110 healthy men aged 30 to 61 years enrolled; 7 analysed13 g glycine or flavoured placebo 30 min before bedtime, with time in bed cut by 25% for 3 nights1Fatigue on a visual analog scale lower on day 1 (p = 0.022), sleepiness not significant (p = 0.098); fatigue questionnaire showed no significant effects; psychomotor vigilance reaction time faster on days 1 and 31
Yamadera 2007 and Inagawa 2006, as listed by Soh and colleagues2Crossover randomised trials, listed by Soh and colleagues as a healthy population (Yamadera) and people dissatisfied with sleep (Inagawa); Bannai and colleagues describe both earlier studies as in people who had complained about their sleep2,1Participant numbers are in the review's table and are not restated here23 g/day taken 1 h before bedtime for 2 consecutive nights (Yamadera) or 4 days (Inagawa)2Bannai and colleagues write that the 3 g dose improved subjective sleep quality (Inagawa) and shortened sleep latency measured by polysomnography (Yamadera)1
Kumar and colleagues, Journal of Gerontology Series A 2023 (GlyNAC)4Double-blind placebo-controlled RCT; NIH/NIA R01 grant and a philanthropic gift to the senior author, who also developed the GlyNAC intervention; tests glycine plus NAC together424 older adults (12 per arm) and 12 young adults4100 mg/kg/d each of glycine and NAC, or 200 mg/kg/d alanine, for 16 weeks4Muscle glutathione up 164% after 16 weeks on GlyNAC with no improvement on placebo; gait speed and strength increased, with a trend toward increasing 6-minute walk distance; no adverse events reported as related to supplements4
Lizzo and colleagues, Frontiers in Aging 2022 (GlyNAC)3Single-centre double-blind randomised placebo-controlled 4-arm trial; authors are employees of Nestlé or of Profil Institute, which ran the trial and has received research funding from Nestlé Health Sciences, a company that markets glycine and NAC products3117 healthy older adults aged 60 to 85 randomised; 114 completed3Glycine 1.2, 2.4 or 3.6 g a day with equal NAC, or isomaltulose placebo, in two daily doses for 14 days3Primary endpoint (total glutathione) no significant difference at any dose; a post hoc subset (high malondialdehyde, low total glutathione, 4.8 and 7.2 g groups pooled) showed a 10.47% rise (p = 0.016); no severe adverse effects3
Soh and colleagues, GeroScience 2024 (systematic review)2Systematic review of 50 studies, 42 of them randomised trials; no pooled analysis2Healthy and diseased adults (18 and 34 studies)2One day (single bolus) to 14 days in healthy people; up to 4 months in diseased populations2Improved sleep and less fatigue in three healthy populations at 3 g/day; negative effects at higher single doses; most trials rated some concerns or high risk of bias2

Deeper analysis: Bannai 2012, sleep restriction

Bannai and colleagues, Frontiers in Neurology, 2012, tested glycine against a flavoured placebo in a randomized single-blinded crossover trial.1 Ten healthy men (30 to 61 years, average 41.4) who worked at Ajinomoto Co., Inc. were enrolled.1 One participant dropped out and two who took medication for influenza and a pollen allergy were excluded, leaving seven for analysis; the text gives no reason for the dropout.1 Time in bed was restricted to 25% less than usual, an average of 5.5 h against 7.3 h usually, for three consecutive nights.1 The participants had no sleep complaints and an average Pittsburgh Sleep Quality Index score of 4.7.1 On day 1 the visual analog scale showed a significant effect on fatigue (p = 0.022) and no significant effect on sleepiness (p = 0.098).1 On the fatigue-complaints questionnaire, "No significant effects were observed between the placebo and glycine treatment groups for any measurement", with tendencies for drowsiness (p = 0.066) and total score (p = 0.080).1 "On day 3, no significant difference was observed between the placebo and glycine treatment groups" for these subjective measures.1 Psychomotor vigilance reaction time was "significantly decreased in glycine group on both day 1 and day 3" (treatment p = 0.003 on day 1 and p = 0.05 on day 3), while "the other tests did not show significant differences".1 The authors write that "The reason for the continued improvement in psychomotor vigilance until day 3 is not clear, and further study is needed on the improvement of both subjective and objective parameters by glycine ingestion".1 The paper reports approval by the Institutional Review Board of Ajinomoto Co., Inc. and a conflict statement that the research was conducted "in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest".1

Deeper analysis: Kumar 2023, GlyNAC in older adults

Kumar and colleagues at Baylor College of Medicine, Journal of Gerontology Series A, 2023, tested GlyNAC, the combination of glycine and N-acetylcysteine, so the trial does not isolate glycine.4 Twenty-four older adults were randomized to GlyNAC (N = 12) or an alanine placebo (N = 12) for 16 weeks, and 12 young adults received GlyNAC for 2 weeks.4 Capsules gave 100 mg/kg/d each of glycine and NAC, against 200 mg/kg/d of alanine, and participants and the study team were blinded.4 The older-adult inclusion criteria were 61 to 80 years, and the GlyNAC and placebo groups averaged 71.4 and 70.8 years.4 Muscle glutathione was 66% lower in the older groups than in young adults at baseline, and only GlyNAC raised it, by 121% after 2 weeks and 164% after 16 weeks, to levels not different from young adults.4 On physical function, "Only GlyNAC supplementation increased gait speed" to levels not different from young adults, and it increased muscle strength, with "a trend toward increasing 6-minute walk distance".4 The aging-hallmark outcomes were exploratory: "Because the aging hallmarks were first reported after our RCT had started, they were added as exploratory outcomes after trial completion".4 For safety, creatinine and transaminases measured at 2, 4, 8, 12 and 16 weeks "did not show any increase compared to baseline values", and "Participants did not report any adverse events related to the use of supplements (GlyNAC or placebo) during the trial".4 The authors state the limitation that "This RCT studied healthier OA to focus primarily on the pure effect of aging unaffected by the additional confounding disease", and that "future GlyNAC trials with larger numbers of more typical OA are warranted".4 Funding came from an NIH/National Institute on Aging R01 grant to the senior author and a philanthropic gift from the McNair Medical Institute at the Robert and Janice McNair Foundation, and the paper states that neither source "played any role in the conduct of the trial, interpretation of results, statistical analysis, or manuscript preparation".4 The conflict-of-interest statement reads "None declared", and the author contributions state that the principal investigator "conceived the hypotheses, designed the trial, obtained funding, developed the GlyNAC intervention".4

Deeper analysis: Lizzo 2022, GlyNAC dose trial in healthy older adults

Lizzo and colleagues, Frontiers in Aging, 2022, ran a single-centre, double-blind, randomized, placebo-controlled 4-arm trial of GlyNAC, so its results belong to glycine plus NAC and not to glycine alone.3 117 older adults aged 60 to 85 were randomized and 114 completed 2 weeks of dosing; 20 young adults served as a non-interventional reference group.3 Daily doses were 2.4 g, 4.8 g or 7.2 g of actives in a 1:1 ratio (1.2, 2.4 or 3.6 g of glycine), against 7.2 g of isomaltulose placebo.3 The primary endpoint, total glutathione compared with placebo at the end of the study, showed "No significant differences" at any dose, and the ratio of reduced to oxidized glutathione was also unchanged (placebo 12.49 against 12.65 at 7.2 g, p = 0.739).3 A post hoc analysis of participants with malondialdehyde above the median and total glutathione below the median, pooling the 4.8 and 7.2 g groups, reported "a 10.47% increase of total glutathione levels" (medians 819.7 to 905.4 mg/L per %Ht, p = 0.016), while the same pooled groups without high oxidative stress showed no change (p = 0.516).3 Safety findings were no severe adverse effects, no discontinuation of GlyNAC because of adverse effects, and three study discontinuations, of which two were because of COVID-19 recommendations to reduce travel and one was for high blood pressure.3 The authors write that they "cannot exclude that GSH levels in tissues other than blood cells were more severely affected by oxidative stress since erythrocytes lack mitochondria", and that "Further studies are warranted to confirm this hypothesis".3 The conflict statement lists the Nestlé-employed authors and says "Nestlé Health Sciences holds patents and licenses to patents and markets products for the use of glycine and n-acetylcysteine in conditions related to impaired mitochondrial functions", and that Profil Institute, which ran the trial, "has received research funding from Nestlé Health Sciences".3

Deeper analysis: Soh 2024, systematic review

Soh and colleagues, GeroScience, 2024, included 47 articles describing 50 studies, 42 of them randomised controlled trials and 41 of them oral glycine.2 In healthy people the review reports that "Improved sleep quality, alertness and cognition, and decreased fatigue and sleepiness was observed in three populations receiving 3 g/day oral administration of glycine".2 Of eight healthy-population nervous-system studies, "one reported inconclusive effects" and another "reported a statistically insignificant effect".2 The review states that "negative effects were mainly reported in studies giving a higher glycine dose in a single bolus".2 The authors' stated limitations are that "the evidence stem from studies of small sample sizes with overall high risk of bias" for sleep, fatigue and alertness in healthy people, that "Publication bias may have skewed analysis toward positive findings", and that "Formal statistical analysis was not conducted and results are interpreted on reported p-values".2 Two studies rated at low overall risk of bias were both parallel-group trials in diseased populations, and none were in healthy people.2 The review gives its conflict statement as "No conflict of interest to declare"; its text carries no funding statement.2

5

Doses reported in studies and on labels

No prescribing label for oral glycine was identified; the rows below are doses reported in studies, a registered trial, and one US food-additive limit. The app lists a typical dose of 3 to 5 g/day by mouth.

Table 5.1Doses reported in studies and on labels8 rows
Dose and routeComparatorPeople, n and lengthReference
3 g oral, 30 min before bedtimeFlavoured placebo (reduced form of malt sugar)7 healthy men analysed of 10 enrolled; 3 nights with time in bed cut by 25%Bannai 20121
3 g/day oral, 1 h before bedtimeFlavoured placebo (reduced form of malt sugar)Healthy population, 2 consecutive nights; n not restated hereYamadera 2007, as listed by Soh 20242
3 g/day oral, 1 h before bedtimeFlavoured placeboPeople dissatisfied with sleep, 4 days; n not restated hereInagawa 2006, as listed by Soh 20242
5 g three times a day oralNot stated in the review's sentenceType 2 diabetes patients, 3 months; the same dose in metabolic syndrome patients was compared with baselineAs summarised by Soh 20242
100 mg/kg/d glycine with 100 mg/kg/d NAC, oral capsulesAlanine 200 mg/kg/d12 older adults per arm, 16 weeksKumar 20234
1.2, 2.4 or 3.6 g glycine a day with equal NAC, oral, two daily doses7.2 g isomaltulose117 randomised, 114 completed, 14 daysLizzo 20223
9 g/day oral capsules (planned)Matching placebo60 participants with fatty liver disease to be randomised, 26 weeks; recruiting, no resultsNCT072851358
Up to 0.2 percent glycine in the finished beverage, as a masking agent for the bitter aftertaste of saccharinNot applicableUS food-additive regulation, 21 CFR 172.812eCFR10

Bannai and colleagues report one dropout among 10 enrolled participants and give no reason; their text reports no adverse event results.1 In the 16-week GlyNAC trial, "Participants did not report any adverse events related to the use of supplements (GlyNAC or placebo) during the trial", and the authors call GlyNAC "safe and well-tolerated"; the supplement contained NAC as well as glycine.4 In the 14-day GlyNAC dosing trial, "No severe adverse effects were reported", none discontinued GlyNAC because of adverse effects, and of three study discontinuations one was because of high blood pressure and two because of COVID-19 travel recommendations.3 The same trial reported "clinically not relevant, but significant changes in ALP" at the 3.6 g and 7.2 g groups against placebo (alkaline phosphatase 70.66 and 70.52 U/L against 60.67 U/L), the authors' wording.3 In the systematic review, "Higher single bolus of 0.8 g/kg body weight orally or 200 mg/kg body weight intravenously showed negative effects on sensorimotor gating and cognitive performance in healthy populations".2 For 5 g three times a day over 3 months in people with metabolic syndrome, the review reports lower A1C but higher fasting blood glucose and total cholesterol compared with baseline.2

7

Bloodwork and markers

The app lists no health markers to monitor for glycine. Lizzo and colleagues measured glycine, total cysteine, total and reduced glutathione, the reduced-to-oxidized glutathione ratio and malondialdehyde in blood.3 At baseline, healthy older adults had significantly lower plasma glycine than young adults (means, young = 271.6, older adults = 229.4 µM, p = 0.01), and the authors report lower fasting glycine levels negatively correlated with insulin resistance (HOMA-IR).3 Kumar and colleagues monitored plasma creatinine, alanine and aspartate transaminases at 2, 4, 8, 12 and 16 weeks of GlyNAC.4

8

Regulatory and anti-doping status

A text search of the WADA 2026 Prohibited List PDF for "glycine" and for "amino acid" returned no match.9 The US food-additive regulation 21 CFR 172.812 states that "The food additive glycine may be safely used for technological purposes in food in accordance with the following prescribed conditions".10 It lists two uses: as a masking agent for the bitter aftertaste of saccharin in manufactured beverages and beverage bases (not to exceed 0.2 percent in the finished beverage), and as a stabilizer in mono- and diglycerides (not to exceed 0.02 percent).10 That regulation covers glycine as a food additive for technological purposes, and the sources reviewed here do not describe a US or EU approval of oral glycine as a drug.

The sources reviewed here give no human half-life or absolute bioavailability figure for oral glycine, so the app's 4 hours and 99% stand without a figure from the sources beside them. Slow-wave sleep is named in the app's notes, and no measurement of slow-wave sleep after glycine was identified in the texts reviewed here. The two original Japanese sleep reports, Yamadera 2007 and Inagawa 2006, were reached only through Soh and Bannai, so their participant numbers, results and funding are not restated here. Soh and colleagues call the evidence for sleep in healthy people small-sample and high risk of bias, and the one trial read in full here had seven analysed participants.2,1 The GlyNAC trials combine glycine with NAC, and Lizzo and colleagues' primary endpoint was not met; the results cannot be read as glycine alone.3 A blend study by Langan-Evans and colleagues, Medicine and Science in Sports and Exercise, 2023, tested "a novel nutritional blend composed of tryptophan, glycine, magnesium, tart cherry powder, and l -theanine" in 16 participants in 3-day intervention and placebo trials and reported a sleep onset latency change of "-24 ± 25 min", which cannot be attributed to glycine.11 A registered trial of 9 g/day glycine in fatty liver disease (NCT07285135, Singapore General Hospital) was recruiting, with 60 participants with the disease to be randomised and 30 healthy controls, and no results were available in the registry entry reviewed.8

What is the half-life of glycine?

The app lists a half-life of about 4 hours for glycine. No human half-life figure for oral glycine was identified in the sources reviewed.

How long does glycine take to reach its peak level?

The app lists about 1 hour, and Lizzo and colleagues cite a published tmax of approximately 75 minutes for glycine in the plasma of healthy volunteers.3

What is the bioavailability of glycine?

The app lists a bioavailability of 99%, and no absolute bioavailability figure for oral glycine was identified in the sources reviewed.

Is glycine banned by WADA?

A text search of the WADA 2026 Prohibited List PDF for "glycine" returned no match.9

Is glycine an essential amino acid?

Bannai and colleagues describe glycine as a non-essential amino acid that mammals can produce by de novo synthesis.1

Does glycine raise melatonin?

In a rat experiment, plasma melatonin was not significantly different between glycine and vehicle.1

Did GlyNAC raise glutathione in healthy older adults?

In Lizzo and colleagues' 14-day trial of 117 randomised older adults, total glutathione was not significantly different from placebo at any of three doses.3 In Kumar and colleagues' 16-week trial of 12 older adults per arm, muscle glutathione rose by 164% on GlyNAC with no improvement on placebo.4

Is the evidence for glycine and sleep strong?

The app grades the evidence for glycine as strong, while Soh and colleagues write that the sleep evidence in healthy people comes from "studies of small sample sizes with overall high risk of bias".2

12

References

  1. Bannai M, et al. The Effects of Glycine on Subjective Daytime Performance in Partially Sleep-Restricted Healthy Volunteers. Front Neurol 2012. PMID 22529837
  2. Soh J, et al. The effect of glycine administration on the characteristics of physiological systems in human adults: A systematic review. GeroScience 2024. PMID 37851316
  3. Lizzo G, et al. A Randomized Controlled Clinical Trial in Healthy Older Adults to Determine Efficacy of Glycine and N-Acetylcysteine Supplementation on Glutathione Redox Status and Oxidative Damage. Front Aging 2022. PMID 35821844
  4. Kumar P, et al. Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial. J Gerontol A Biol Sci Med Sci 2023. PMID 35975308
  5. Kawai N, et al. The sleep-promoting and hypothermic effects of glycine are mediated by NMDA receptors in the suprachiasmatic nucleus. Neuropsychopharmacology 2015. PMID 25533534
  6. Bannai M, Kawai N. New therapeutic strategy for amino acid medicine: glycine improves the quality of sleep. J Pharmacol Sci 2012. PMID 22293292
  7. Gannon MC, et al. The metabolic response to ingested glycine. Am J Clin Nutr 2002. PMID 12450897
  8. Singapore General Hospital. Dietary Glycine Supplementation in Metabolic Dysfunction-associated Steatotic Liver Disease. ClinicalTrials.gov NCT07285135. NCT07285135
  9. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list
  10. US Food and Drug Administration. 21 CFR 172.812, Glycine. Electronic Code of Federal Regulations. eCFR 21 CFR 172.812
  11. Langan-Evans C, et al. Nutritional Modulation of Sleep Latency, Duration, and Efficiency: A Randomized, Repeated-Measures, Double-Blind Deception Study. Med Sci Sports Exerc 2023. PMID 36094342